Hexagon Capital Partners’s Oragenics OGEN Stock Holding History

Hexagon Capital Partners’s Portfolio OGEN Stock Details OGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9	Closed	-$58	–	1188
2025 Q1	$58	Buy	+9	New	+$78	﹤0.01%	1811

Other funds holding OGEN

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

LWM

Lionsbridge Wealth Management Jacksonville Beach, Florida $102M AUM 28.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Hexagon Capital Partners's OGEN Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Oragenics (OGEN) in Q2 2025, closing a stake of 9 shares — an estimated $58 sold.

Hexagon Capital Partners first reported a position in OGEN in Q1 2025 and held it in 1 quarter. The position peaked at $58 in Q1 2025. 18 funds tracked by Wall St. Rank hold OGEN as of Q2 2025.

Hexagon Capital Partners reported no remaining Oragenics position as of Q2 2025 after selling out during the quarter.
Hexagon Capital Partners sold 9 Oragenics shares in Q2 2025, an estimated $58.
Hexagon Capital Partners first reported a position in Oragenics in Q1 2025 and held it in 1 quarter.
Hexagon Capital Partners's Oragenics position peaked at $58 in Q1 2025.
18 funds tracked by Wall St. Rank held Oragenics as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.